Senseonics Holdings, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Senseonics Holdings, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $16.39M | Mar 16, 2023 |
| FY2022 | Dec 31, 2021 | $13.68M | Mar 16, 2023 |
| FY2020 | Dec 31, 2020 | $3.89M | Mar 5, 2021 |
| FY2020 | Sep 30, 2020 | $767.0K | Mar 5, 2021 |
| FY2020 | Jun 30, 2020 | $261.0K | Mar 5, 2021 |
| FY2020 | Mar 31, 2020 | $36.0K | Mar 5, 2021 |
| FY2020 | Dec 31, 2019 | $8.95M | Mar 5, 2021 |
| FY2020 | Sep 30, 2019 | $4.32M | Mar 5, 2021 |
| FY2020 | Jun 30, 2019 | $4.61M | Mar 5, 2021 |
| FY2020 | Mar 31, 2019 | $3.42M | Mar 5, 2021 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $35.26M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $22.47M | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | $22.39M | Mar 3, 2025 |
| FY2023 | Dec 31, 2022 | $16.39M | Mar 1, 2024 |
| FY2022 | Dec 31, 2021 | $1.39M | Mar 16, 2023 |
| FY2022 | Dec 31, 2020 | $1.37M | Mar 16, 2023 |
| FY2021 | Dec 31, 2019 | $4.92M | Mar 1, 2022 |
| FY2018 | Dec 31, 2018 | $7.19M | Mar 15, 2019 |
| FY2018 | Sep 30, 2018 | $5.16M | Mar 15, 2019 |
| FY2018 | Jun 30, 2018 | $3.62M | Mar 15, 2019 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $15.76M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $533.0K | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | $3.09M | Mar 3, 2025 |
| FY2023 | Dec 31, 2022 | $2.73M | Mar 1, 2024 |
| FY2022 | Dec 31, 2021 | ($811.0K) | Mar 16, 2023 |
| FY2020 | Dec 31, 2020 | $2.58M | Mar 5, 2021 |
| FY2020 | Sep 30, 2020 | $835.0K | Mar 5, 2021 |
| FY2020 | Jun 30, 2020 | ($1.14M) | Mar 5, 2021 |
| FY2020 | Mar 31, 2020 | ($19.63M) | Mar 5, 2021 |
| FY2020 | Dec 31, 2019 | ($8.24M) | Mar 5, 2021 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($69.11M) | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | ($78.62M) | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | ($60.39M) | Mar 3, 2025 |
| FY2023 | Dec 31, 2022 | $142.12M | Mar 1, 2024 |
| FY2022 | Dec 31, 2021 | ($302.47M) | Mar 16, 2023 |
| FY2020 | Dec 31, 2020 | ($101.63M) | Mar 5, 2021 |
| FY2020 | Sep 30, 2020 | ($23.43M) | Mar 5, 2021 |
| FY2020 | Jun 30, 2020 | ($7.52M) | Mar 5, 2021 |
| FY2020 | Mar 31, 2020 | ($42.59M) | Mar 5, 2021 |
| FY2020 | Dec 31, 2019 | ($35.61M) | Mar 5, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($68.34M) | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | ($74.84M) | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | ($75.60M) | Mar 3, 2025 |
| FY2023 | Dec 31, 2022 | ($68.63M) | Mar 1, 2024 |
| FY2022 | Dec 31, 2021 | ($57.18M) | Mar 16, 2023 |
| FY2020 | Dec 31, 2020 | ($10.31M) | Mar 5, 2021 |
| FY2020 | Sep 30, 2020 | ($12.47M) | Mar 5, 2021 |
| FY2020 | Jun 30, 2020 | ($12.53M) | Mar 5, 2021 |
| FY2020 | Mar 31, 2020 | ($43.83M) | Mar 5, 2021 |
| FY2020 | Dec 31, 2019 | ($34.88M) | Mar 5, 2021 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $31.59M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $41.14M | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | $48.75M | Mar 3, 2025 |
| FY2023 | Dec 31, 2022 | $39.72M | Mar 1, 2024 |
| FY2022 | Dec 31, 2021 | $27.22M | Mar 16, 2023 |
| FY2022 | Dec 31, 2020 | $20.41M | Mar 16, 2023 |
| FY2021 | Dec 31, 2019 | $38.43M | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $31.86M | Mar 5, 2021 |
| FY2019 | Dec 31, 2017 | $30.74M | Mar 16, 2020 |
| FY2018 | Dec 31, 2016 | $26.35M | Mar 15, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $52.51M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $34.23M | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | $29.94M | Mar 3, 2025 |
| FY2023 | Dec 31, 2022 | $31.63M | Mar 1, 2024 |
| FY2022 | Dec 31, 2021 | $29.15M | Mar 16, 2023 |
| FY2022 | Dec 31, 2020 | $41.35M | Mar 16, 2023 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($59.13M) | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | ($60.47M) | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | ($70.16M) | Mar 3, 2025 |
| FY2023 | Dec 31, 2022 | ($66.31M) | Mar 1, 2024 |
| FY2022 | Dec 31, 2021 | ($56.08M) | Mar 16, 2023 |
| FY2022 | Dec 31, 2020 | ($67.42M) | Mar 16, 2023 |
| FY2021 | Dec 31, 2019 | ($136.05M) | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | ($90.77M) | Mar 5, 2021 |
| FY2019 | Dec 31, 2017 | ($55.74M) | Mar 16, 2020 |
| FY2018 | Dec 31, 2016 | ($38.02M) | Mar 15, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $126.27M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $100.44M | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | $138.22M | Mar 3, 2025 |
| FY2023 | Dec 31, 2022 | $177.67M | Mar 1, 2024 |
| FY2022 | Dec 31, 2021 | $198.93M | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | $35.92M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $132.80M | Mar 5, 2021 |
| FY2019 | Dec 31, 2018 | $159.97M | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | $45.94M | Mar 15, 2019 |
| FY2017 | Dec 31, 2016 | $22.27M | Mar 13, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $65.22M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $79.34M | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | $64.77M | Mar 3, 2025 |
| FY2023 | Dec 31, 2022 | $142.59M | Mar 1, 2024 |
| FY2022 | Dec 31, 2021 | $384.46M | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | $177.19M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $141.45M | Mar 5, 2021 |
| FY2019 | Dec 31, 2018 | $88.71M | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | $38.68M | Mar 15, 2019 |
| FY2017 | Dec 31, 2016 | $27.15M | Mar 13, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $61.05M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | ($16.56M) | Mar 2, 2026 |
| FY2025 | Dec 31, 2023 | $35.80M | Mar 2, 2026 |
| FY2024 | Dec 31, 2022 | ($2.58M) | Mar 3, 2025 |
| FY2023 | Dec 31, 2021 | ($185.54M) | Mar 1, 2024 |
| FY2022 | Dec 31, 2020 | ($144.08M) | Mar 16, 2023 |
| FY2022 | Dec 31, 2019 | ($8.65M) | Mar 16, 2023 |
| FY2021 | Dec 31, 2018 | $71.26M | Mar 1, 2022 |
| FY2020 | Dec 31, 2017 | $7.27M | Mar 5, 2021 |
| FY2019 | Dec 31, 2016 | ($4.88M) | Mar 16, 2020 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($1.02B) | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | ($947.87M) | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | ($869.26M) | Mar 3, 2025 |
| FY2023 | Dec 31, 2022 | ($808.87M) | Mar 1, 2024 |
| FY2022 | Dec 31, 2021 | ($950.99M) | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | ($648.51M) | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | ($473.34M) | Mar 5, 2021 |
| FY2019 | Dec 31, 2018 | ($357.79M) | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | ($263.82M) | Mar 15, 2019 |
| FY2017 | Dec 31, 2016 | ($204.72M) | Mar 13, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $40.23M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $74.60M | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | $75.71M | Mar 3, 2025 |
| FY2023 | Dec 31, 2022 | $35.79M | Mar 1, 2024 |
| FY2022 | Dec 31, 2021 | $33.46M | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | $18.01M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $95.94M | Mar 5, 2021 |
| FY2019 | Dec 31, 2018 | $136.79M | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | $16.15M | Mar 15, 2019 |
| FY2017 | Dec 31, 2016 | $13.05M | Mar 13, 2018 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $35.59M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | $34.70M | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | $41.20M | Mar 3, 2025 |
| FY2023 | Dec 31, 2022 | $56.38M | Mar 1, 2024 |
| FY2022 | Dec 31, 2021 | $59.80M | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | $57.22M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $11.80M | Mar 5, 2021 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | (2) | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 3, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 1, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 16, 2023 |
| FY2022 | Dec 31, 2020 | 0 | Mar 16, 2023 |
| FY2021 | Dec 31, 2019 | 0 | Mar 1, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | (2) | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 3, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 1, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 16, 2023 |
| FY2022 | Dec 31, 2020 | 0 | Mar 16, 2023 |
| FY2021 | Dec 31, 2019 | 0 | Mar 1, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 41.27M | Mar 2, 2026 |
| FY2025 | Dec 31, 2024 | 29.77M | Mar 2, 2026 |
| FY2024 | Dec 31, 2023 | 530.36M | Mar 3, 2025 |
| FY2023 | Dec 31, 2022 | 479.64M | Mar 1, 2024 |
| FY2022 | Dec 31, 2021 | 447.28M | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | 265.58M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | 203.45M | Mar 5, 2021 |
| FY2019 | Dec 31, 2018 | 176.92M | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | 136.88M | Mar 15, 2019 |
| FY2017 | Dec 31, 2016 | 93.57M | Mar 13, 2018 |